A Study to Evaluate the Pharmacokinetics (PK) and Safety of DUR-928 in Subjects with Impaired Kidney Function and Matched Control Subjects with Normal Kidney Function
Latest Information Update: 04 Jul 2019
Price :
$35 *
At a glance
- Drugs Larsucosterol (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors DURECT Corporation
- 25 Oct 2018 According to a DURECT Corporation media release, data will be presented at the American College of Toxicology's Annual Meeting.
- 08 Aug 2017 According to a DURECT Corporation media release, status changed from recruiting to completed.
- 10 May 2017 According to a DURECT Corporation media release, the company expects to complete this study shortly.